Full Press Release Details
Fresenius Medical Care AG nominates Six Employee Representatives
to the Supervisory Board
Bad Homburg (February 5, 2024)
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has
nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court
approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located
Fresenius Medical Care successfully completed its change of legal
form into a German stock corporation (Aktiengesellschaft, AG) on November 30, 2023, which also included the formation of a new Supervisory
Board, which initially consisted of the six shareholder representatives. With the appointment of the six employee representatives, the
Supervisory Board now has full and equal representation. The Board comprises six women and six men and is well above the statutory minimum gender quota for the Supervisory Board of 30 percent
The employee representatives of the Supervisory Board include four
FME employees, including the representative for executive employees in Germany, and two representatives of the Industriegewerkschaft
Bergbau, Chemie, Energie (IGBCE / Industrial Union of Mining, Chemistry, Energie). The appointed members of the Supervisory Board are:
Michael Sen, Chairman of the
Supervisory Board of Fresenius Medical Care AG, says: "The proposed employee representatives provide a broad range of experience and
knowledge to the Supervisory Board. I look forward to a trusted and constructive collaboration to pursue our common goal to further developing
Fresenius Medical Care successfully to the benefit patients, employees and shareholders."
Following the appointment, Fresenius Medical Care is preparing the election of the employee representatives to the Supervisory Board,
following legal requirements. The election is expected to be completed in the second half of 2024.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment.
Through its network of 4,050dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients
around the globe and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is
listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's
website at www.freseniusmedicalcare.com.
This release contains forward-looking statements
that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking
statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties
in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in
Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake
any responsibility to update the forward-looking statements in this release.